TITLE

Agreements/contracts

PUB. DATE
October 2010
SOURCE
Medical Device Daily;10/15/2010, Vol. 14 Issue 201, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on a partnership and license agreement between San Diego, California-based Fate Therapeutics and Becton, Dickson and Co. (BD) for the manufacturing and commercialization of induced pluripotent stem cell (iPSC) instruments and technologies for drug development.
ACCESSION #
54461156

 

Related Articles

  • Fate Strikes Technology Deal to Expand R&D IPSC Tools.  // Bioworld Week;10/18/2010, Vol. 18 Issue 42, p5 

    The article reports on the collaboration and license agreement between Fate Therapeutics Inc. and BD Biosciences for the expansion of Fate's research and development technology for induced pluripotent stem cells (iPSC).

  • Fate Strikes Technology Deal to Expand R&D IPSC Tools. Boggs, Jennifer // BioWorld Today;10/14/2010, Vol. 21 Issue 199, p1 

    The article reports on a licensing agreement deal of Fate Therapeutics Inc. with BD Biosciences that could make its induced pluripotent stem cells (iPSC) technology available across the research community, while boosting its own iPSC-based therapeutic efforts in the process. The licensing deal...

  • Takeda Tempted by Fate; Adds to Regenerative Medicine Effort. Boggs, Jennifer // BioWorld Today;5/11/2011, Vol. 22 Issue 91, p2 

    The article announces that Takeda Ventures Inc. has become an investor of Fate Therapeutics Inc. through the latter's approach to stem cell therapy which focuses on the development of small-molecule drugs that intend to modulate adult stem cells. Takeda has also participated in other deals such...

  • Merck, Spanish CNIO Enter License Agreement.  // Contract Pharma;Jan/Feb2014, Vol. 16 Issue 1, p78 

    The article reports that the pharmaceutical company Merck Serono has entered a license agreement with the Spanish National Cancer Research Centre (CNIO) to develop new cancer drug.

  • Valuation of complex license contracts. Villiger, Ralph; Bogdan, Boris // Journal of Commercial Biotechnology;Oct2009, Vol. 15 Issue 4, p301 

    Licensing is an important business model within the drug development industry. Recently license contracts have become extremely complex, including sublicensing, co-development, or profit sharing. Traditional rules of thumb are not sufficient anymore as guidelines in negotiations of deal terms....

  • Dormant Opportunity?  // Pharmaceutical Executive;Apr2005, Vol. 25 Issue 4, p32 

    Reports on the percentage of late-stage in-licensing deals among pharmaceutical firms in the U.S. Entry into strategic alliances with biotechnology companies; Cost implications of late-stage development; Shift in the risk/reward balance of the licensing process.

  • Isis Licenses Its Costly Diabetes Drug Development. Webb, Marion // San Diego Business Journal;5/28/2001, Vol. 22 Issue 22, p9 

    Reports the licensing agreement of Isis Pharmaceuticals Inc. and Merck & Co. in San Diego, California. Benefits of the agreement to Isis; Development of the diabetes drug candidate ISIS3715; Impact of the agreement on Merck & Co.

  • PHARMA? THINK SMALL. Simons, John // Fortune International (Europe);3/20/2006, Vol. 153 Issue 5, p81 

    The article examines investment in small pharmaceutical companies, which are creating many new drugs. Unlike large pharmaceutical companies, small ones concentrate their research in one particular area such as cancer, heart disease, or central nervous system disorders. When these companies...

  • PHARMA? THINK SMALL. Simons, John // Fortune;3/20/2006, Vol. 153 Issue 5, p167 

    The article examines investment in small pharmaceutical companies, which are creating many new drugs. Unlike large pharmaceutical companies, small ones concentrate their research in one particular area such as cancer, heart disease, or central nervous system disorders. When these companies...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics